Evidence map›Paper›PMID 39806999›Full record

ReviewJournal of the Chinese Medical Association : JCMA2025

Intracerebral hemorrhage in CADASIL.

Shao-Lun Hsu, Yi-Chu Liao, Chih-Ping Chung, Masafumi Ihara, Jay Chol Choi, Sung-Chun Tang, Yi-Chung Lee

Abstract readReview
In one paragraph

Review in Journal of the Chinese Medical Association : JCMA, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shao-Lun HsuInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Yi-Chu LiaoDepartment of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Chih-Ping ChungDepartment of Neurology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
Masafumi IharaDepartment of Neurology, National Cerebral and Cardiovascular Center, Suita, Japan.
Jay Chol ChoiDepartment of Neurology, Jeju National University College of Medicine, Jeju National University Hospital, Jeju, Korea.
Sung-Chun TangDepartment of Neurology, National Taiwan University Hospital, Taipei, Taiwan, ROC.
Yi-Chung LeeInstitute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common hereditary cerebral small vessel disease caused by mutations in the NOTCH3 gene. This review highlights the increasing recognition of intracerebral hemorrhage (ICH) as a significant manifestation of CADASIL, often predominantly characterized by ischemic strokes and vascular dementia. Recent studies indicate that the prevalence of ICH in CADASIL patients ranges from 0.5% to 33.3%, the variability of which is mainly influenced by ethnicity. In East Asian cohorts, specific NOTCH3 mutations like p.R544C and p.R75P are more prevalent and have been associated with a higher rate of ICH, suggesting a link between these mutations and the hemorrhagic risk. Hypertension, as with other etiologies of ICH, is a key risk factor in CADASIL patients, with 40% to 90% of those who experience ICH also having a history of hypertension. The presence of cerebral microbleeds (CMBs) and a high CMB load are strongly associated with an increased risk of ICH. Neuroimaging studies show that ICH in CADASIL patients predominantly occurs in the thalamus and basal ganglia. There is a notable spatial correlation between CMBs and subsequent ICH, suggesting that CMBs may serve as markers of microangiopathy in regions prone to vascular injury. CADASIL patients with ICH experience greater morbidity, higher mortality rates, and increased annual stroke recurrence risk compared with those with ischemic events. In summary, this review emphasizes the need for tailored management strategies that prioritize rigorous blood pressure control and the careful use of antithrombotic agents in CADASIL patients with a high burden of CMBs. By advancing our understanding of ICH in CADASIL, we aim to improve diagnostic and therapeutic approaches, ultimately enhancing patient outcomes and quality of life in this high-risk population.

Indexed as

CADASILCerebral HemorrhageHumansMutationReceptor, Notch3Risk FactorsNOTCH3 protein, humanReceptor, Notch3

Identifiers

PMID39806999
PMCPMC12718848

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.